What is the incidence/prevalence, healthcare resource utilization (HCRU) and other outcomes of dedifferentiated liposarcoma (DDLPS) in Canada?

Client: Sunnybrook Health Sciences Centre HOPE Research Centre

Project ID: P2023-172 / 2024 0970 368 000

Research Question/Objectives: Boehringer Ingelheim Canada Ltd. (BICL) is looking to analyze provincial information specific to individuals with dedifferentiated liposarcoma (DDLPS) in order to determine specific clinical and economic outcomes.

Objectives:

Primary objectives:

To estimate the number and rate of incident and prevalent cases of DDLPS;
To assess HCRU outcomes related to DDLPS;
To describe how patients are treated for DDLPS and the sequence of treatment received (1L, 2L, 3L) with treatments including surgery, radiotherapy, chemotherapy and targeted therapies;
To assess overall survival of DDLPS

Secondary objectives:

To conduct primary objectives based on advanced, metastatic, recurrent and unresectable DDLPS status;
To conduct primary objectives based on disease stage and year of DDLPS diagnosis (before and after 2010).

Results: In progress